As part of the exit negotiations the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the United Kingdom and the EU. While it would not be appropriate to pre-judge the outcome of the negotiations, the Government’s position was clarified in an open letter to The Financial Times, dated 5 July 2017. In that letter we made clear that our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.